Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Indiana for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Indiana only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Indiana (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Mohamad Kassar (NPI 1063691830)

Field	Value
Entity Type	Individual
Organization	Mohamad Kassar
Address	1001 Calumet Ave
City	Dyer
State	IN
ZIP	46311
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	October 30, 2007

Payer Source	Total Paid
Medicare	$4.7M
Medicaid	$0

Key Findings

MOHAMAD KASSAR is effectively a Medicare-focused hematology/oncology practice: lifetime Medicare revenue totals $4.7M while there is no Medicaid billing on file, indicating the provider operates with a single-payer footprint in available claims data rather than a mixed payer panel. This concentration suggests operations, contracting, and patient mix are driven almost entirely by Medicare reimbursement and beneficiary referrals.

Revenue concentration is highly skewed toward a few high-cost oncology drugs: the precomputed top 3 Medicare codes by revenue account for 59.2% of total Medicare revenue, with J9271 alone comprising 39.3% of Medicare revenue. That level of concentration indicates the practice’s revenue stream is dominated by immunotherapy infusions and a small set of injectable oncology agents.

The code mix shows an infusion-heavy oncology service line: J9271 (pembrolizumab), J9299 (nivolumab), and J9022 (atezolizumab) are the top revenue drivers, and the presence of multiple monoclonal antibody and oncology infusion codes (also including bevacizumab J9035 and various supportive-care injectables like J0897 denosumab and biosimilar pegfilgrastim Q5122) signals a practice structured around outpatient infusion therapy rather than primarily procedural or surgical oncology.

Competitive standing for key immunotherapy and infusion codes is strong nationally: J9271 ranks #28 of 1841 providers (98th percentile) indicating notably above-typical national volume for pembrolizumab, while J9035 (bevacizumab) ranks #13 of 1852 (99th percentile) and 96413 chemotherapy administration ranks at the 100th percentile and is described as an extreme outlier. These rankings point to MOHAMAD KASSAR being a high-volume national outlier for several infusion and chemotherapy administration codes.

Several non-drug services and common lab tests also appear at unusually high volumes relative to peers, consistent with a high-throughput infusion center model: office E/M codes 99214 and 99213 are extreme outliers (100th and 99th percentiles respectively), and a cluster of routine lab CPTs (85025, 84132, 84295, 82310, 84450, 82247, 84075, 84460) rank in the 98th–99th percentiles, reflecting frequent pre-/post-infusion monitoring and on-site phlebotomy. This pattern reinforces the interpretation of substantial patient throughput and integrated ancillary services.

Tenure in the Medicare program is long: the provider’s NPI was enumerated on 2007-10-30 (~19 years ago), indicating nearly two decades of presence in claims data and suggesting an established referral and operational footprint in the market.

While several codes are labelled as "extreme outlier" or "notably above typical national volume," others are characterized as "typical, unremarkable volume" despite contributing materially to revenue (for example, J9299 and J9022). This mix indicates the provider combines exceptionally high volume in a few flagship drugs with more typical utilization of other oncology agents, rather than uniformly elevated billing across all oncology codes.

The absence of Medicaid billing means the provider’s competitive and risk profile should be evaluated primarily in the Medicare context: network participation, utilization management, and value-based arrangements with Medicare or Medicare Advantage plans will be the most relevant levers for payers assessing cost and quality implications tied to this provider’s infusion-heavy, high-volume oncology practice.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

91 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	39,600	$40	$1.7M
J9299	Injection, nivolumab, 1 mg	21,700	$20	$520.8K
J9022	Injection, atezolizumab, 10 mg	5,330	$60	$341K
J0897	Injection, denosumab, 1 mg	18,300	$20	$329.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	2,920	$90	$257.1K
J1437	Injection, ferric derisomaltose, 10 mg	7,800	$20	$132.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,330	$90	$123.4K
J9035	Injection, bevacizumab, 10 mg	2,220	$50	$117.7K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	1,120	$100	$111.6K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	4,220	$30	$105.6K

Showing 1–10 of 91

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 91 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Indiana Distribution

Mohamad Kassar — 20 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Indiana

Full comparison — all codes billed, vs. state median

91 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	20	11,200	$40	$631.7K
J9299	2	10	21,700	$20	$498.3K
J9022	1	10	4,910	$60	$314.9K
Q5119	1	10	4,380	$20	$97.4K
J1449	2	10	3,300	$30	$95.5K
J0641	1	10	64,500	$1	$87.8K
J0897	5	220	2,730	$20	$74.9K
J1437	2	20	2,050	$20	$60.3K
Q5122	1	10	430	$100	$46.9K
J2506	8	10	370	$80	$33.1K

Showing 1–10 of 91

Related Providers

Other providers that share a Tax Identification Number (TIN) with Mohamad Kassar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Community Care Network Inc	IN	Family Medicine Physician	$0	$33.9M
St Catherine Hospital Inc	IN	General Acute Care Hospital	$0	$32.3M
Franciscan Health Crown Point	IN	General Acute Care Hospital	$0	$11.4M
Ramon Lee	IL	Retina Specialist (Ophthalmology) Physician	$4M	$8.5K
Sohail Hasan	IL	Retina Specialist (Ophthalmology) Physician	$3.4M	$34.2K
Neel Shah	IN	Hematology & Oncology Physician	$3.2M	$0
Raja Devanathan	IN	Pulmonary Disease Physician	$3M	$0
Michael Tallarico	IN	Medical Oncology Physician	$2.7M	$0
Kourous Rezaei	IL	Retina Specialist (Ophthalmology) Physician	$2.7M	$0
Northwest Cancer Centers, PC	IN	Internal Medicine Physician	$0	$2.5M

Nearby Providers

Other providers in the same ZIP code as Mohamad Kassar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Franciscan Health Dyer & Hammond	IN	General Acute Care Hospital	$0	$4.5M
Tae'ni Chang-stroman M.d., P.C.	IN	Pediatrics Physician	$0	$3.5M
Cannan Healthcare Services & Staffing Inc	IN	Home Health Agency	$0	$3.2M
Pathology Consultants Inc	IN	Anatomic Pathology & Clinical Pathology Physician	$0	$2.9M
Gowri Ramadas	IN	Hematology & Oncology Physician	$1.3M	$0
Shruti Singh	IN	Hematology & Oncology Physician	$1.1M	$0
Kunwarjit Duggal	IN	Physical Medicine & Rehabilitation Physician	$669.7K	$18.8K
Donna Ward	IN	Dermatology Physician	$579.4K	$0
Laura Hoffman	IN	Dermatology Physician	$493.4K	$0
Trevor Marcotte	IN	Family Medicine Physician	$477.8K	$0

Mohamad Kassar — Billing Profile & Reimbursement Data

Sign up for Mohamad Kassar — Billing Profile & Reimbursement Data policy alerts

Mohamad Kassar — Billing Profile & Reimbursement Data

Sign up for Mohamad Kassar — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References